The Trial of SHR6508 in Secondary Hyperparathyroidism
The study is being conducted to evaluate the efficacy and safety of SHR6508 among Chinese patients with secondary hyperparathyroidism of chronic kidney disease treated by maintenance hemodialysis.
Secondary Hyperparathyroidism
DRUG: SHR6508 plus oral placebo tablets|DRUG: Cinacalcet plus intravenous placebo
Proportion of Participants to End of Study whose iPTH decreased by>30% from baseline, iPTH was tested at a central laboratory., efficacy assessment period, defined as Week 20-27
Proportion of Participants to End of Study whose iPTH decreased by>50% from baseline, iPTH was tested at a central laboratory., efficacy assessment period, defined as Week 20-27|Incidence of nausea and vomiting events, Terms were coded with Medical Dictionary for Regulatory Activities (MedDRA), Day1 to End of Treatment, End of Treatment is about Week 27|Proportion of Participants to End of Treatment whose iPTH decreased to 300 pg/mL from baseline, iPTH was tested at a central laboratory., efficacy assessment period, defined as Week 20-27|Change From Baseline in serum cCa and P, cCa and P were tested at a central laboratory., efficacy assessment period, defined as Week 20-27|Participants With Treatment-Emergent Adverse Events (TEAEs), Terms were coded with Medical Dictionary for Regulatory Activities (MedDRA), Day1 to End of Study, End of Study is about Week 31|Participants with Anti-SHR6508 Antibody at baseline and postbaseline, Anti-SHR6508 Antibody was measured in patient serum samples using a validated enzyme-linked immunosorbent assay (ELISA) method., Day1 to End of Study, End of Study is about Week 31
The study is being conducted to evaluate the efficacy and safety of SHR6508 among Chinese patients with secondary hyperparathyroidism of chronic kidney disease treated by maintenance hemodialysis.